Skip to main content

OKYO Pharma Ltd

OKYO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001849296

In the last 90 days, OKYO Pharma Ltd insiders filed 7 open-market purchases and 0 sales; 19 institutions reported holding it in 13F filings for Q2 2026, worth $9.74M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by OKYO Pharma Ltd insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
7 filings
6 insiders, $136.0K in total
Open-market sells
0 filings
Insiders trading
6
Net value
+$136.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for OKYO Pharma Ltd, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for OKYO Pharma Ltd
NameTitleLast reported holdingLast filingFilings, past year
Brancaccio John PDirector35,201Aug 7, 20262
Dempsey Robert JohnCHIEF EXECUTIVE OFFICER15,000Aug 7, 20261
Jacob Gary SCHIEF DEVELOPMENT OFFICER112,420Aug 7, 20261
Cerrone Gabriele MDirector, 10% Owner10,873,916IndirectAug 7, 20263
Mantelli FlavioCHIEF MEDICAL OFFICER20,000Aug 7, 20261
Patil Rajkumar V.Chief Scientific Officer20,030Aug 7, 20261
Simon Willy JulesDirector–Jun 10, 20261
Denoyer BernardDirector–Jun 10, 20261
Shah Keeren RameshchandraChief Financial Officer–Jun 10, 20261

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 7, 2026 (view filing)4:15 PM ETJul 2117 daysBrancaccio John PDirectorPPurchase+5.00K$1.48+$7.38K+16.6%35.2K afterAmended
Aug 7, 2026 (view filing)4:15 PM ETJul 2216 daysDempsey Robert JohnCHIEF EXECUTIVE OFFICERPPurchase+15.0K$1.54+$23.1KNew position15.0K afterAmended
Aug 7, 2026 (view filing)4:15 PM ETJul 2117 daysJacob Gary SCHIEF DEVELOPMENT OFFICERPPurchase+3.50K$1.40+$4.90K+3.2%112.4K afterAmended
Aug 7, 2026 (view filing)4:15 PM ETJul 2117 daysCerrone Gabriele MDirector, 10% OwnerPPurchase+22.5K$1.45+$32.6K+0.2%10.9M afterAmended
Aug 7, 2026 (view filing)4:15 PM ETJul 2018 daysCerrone Gabriele MDirector, 10% OwnerPPurchase+25.0K$1.40+$35.0K+0.2%10.9M afterAmended
Aug 7, 2026 (view filing)4:15 PM ETJul 2117 daysMantelli FlavioCHIEF MEDICAL OFFICERPPurchase+20.0K$1.40+$28.0KNew position20.0K afterAmended
Aug 7, 2026 (view filing)4:15 PM ETJul 2711 daysPatil Rajkumar V.Chief Scientific OfficerPPurchase+3.36K$1.49+$5.01K+20.2%20.0K afterAmended
Sep 28, 2023 (view filing)Sep 1513 daysLateBrancaccio John PDirectorPPurchase+16.7K$1.50+$25.0KNew position16.7K after
May 20, 2022 (view filing)10:35 AM ETMay 191 dayCerrone Gabriele MExecutive ChairmanPPurchase+5.80M$0.076+$440.8K+1.1%549.0M after
May 19, 2022 (view filing)May 19Same dayJacob Gary SChief Executive OfficerPPurchaseAmerican Depositary Shares+12.5K$4.00+$50.0KNew position12.5K after
May 19, 2022 (view filing)May 19Same dayCerrone Gabriele MNon-Executive ChairmanPPurchaseAmerican Depositary Shares+37.5K$4.00+$150.0K+150.0%62.5K after
May 18, 2022 (view filing)11:37 AM ETMay 171 dayCerrone Gabriele MNon-Executive ChairmanPPurchase+1.63M$0.0595+$96.7K+0.3%544.8M after
May 18, 2022 (view filing)May 171 dayCerrone Gabriele MNon-Executive ChairmanPPurchaseAmerican Depositary Shares+25.0K$3.87+$96.8KNew position25.0K afterAmended